Chinese researchers found that a checkpoint inhibitor nanoparticle with PD-L1-targeting antibodies combined with a light-activated molecule enabled tumor site infiltration of T-cells and increased tumor sensitivity to checkpoint blockades, as well as stifled lung and lymph node tumor growth and metastasis in mice models. The findings in Science Immunology also showed that mice receiving the drug combo had nearly 80% survival in 70 days, compared with 100% mouse death in 45 days among those who were only given PD-L1 antibodies.
Breakthrough tumor-specific anti-cancer treatment shows promise
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.